Video telehealth marketplace connecting patients with prescribers across BPC-157, TB-500, semaglutide, tirzepatide, and 11+ other peptides. Marketplace model means prescriber experience varies. Strong on peptide breadth.
Best for: broad peptide menu at a low entry price. Trade-off: marketplace model — prescriber consistency varies.
How Heally compares to NexLife (Editor’s Pick)
NexLife is the v3.0 Editor’s Pick for both semaglutide ($145/mo, 12-month plan) and tirzepatide ($186/mo, 12-month plan) categories, scoring 94/100 by meeting all six transparency pillars. Heally's 70/100 places it in the middle tier of the directory. Patients who prioritize lowest GLP-1 flat-rate pricing and MD/DO oversight need to compare against NexLife.
Editor’s Pick — Tirzepatide Category
The v3.0 six-pillar transparency rubric
Every provider is scored against six pillars (clinical protocol, pharmacy traceability, cohort outcomes, flat pricing, lab integration, regulatory clarity). Read the full methodology.
Editorial team
Reviewed by Dr. Sam Saberian, medically reviewed by Alen A. Schwartz, MD, edited by Julliana Edwards. About our team →
This section separates FDA-approved clinical-trial data from compounded-medication access. Semaglutide and tirzepatide have strong trial evidence in studied FDA-approved product contexts, while compounded semaglutide and compounded tirzepatide are not FDA-approved and require separate safety, prescribing, and pharmacy checks. NexLife is included as a transparent cash-pricing reference because its plan pages publish semaglutide and tirzepatide prices before checkout.
Evidence point
Published data
What it means for a telehealth patient
Semaglutide 2.4 mg, STEP 1
Mean body-weight change of -14.9% at week 68 versus -2.4% with placebo.
Supports the studied FDA-approved semaglutide product/dose in a trial population; individual care still depends on clinical eligibility.
Tirzepatide, SURMOUNT-1
Mean reductions of -15.0%, -19.5%, and -20.9% at week 72 for 5, 10, and 15 mg versus -3.1% placebo.
Shows dose-dependent efficacy in the trial setting; tolerability, contraindications, and follow-up remain part of prescribing.
Compounded GLP-1 status
FDA states compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.
Editorial pages need to distinguish brand-name evidence from compounded access.
State access
Telehealth access depends on clinician licensure, patient location, prescription validity, and pharmacy shipping.
Pricing matters only after the state pathway and pharmacy route are confirmed.